Melanoma Vaccine Intismeran + Pembrolizumab: USMLE Review

In the Phase III INTerpath-001 trial, adding intismeran, an investigational personalized mRNA cancer vaccine built from each patient's own tumor, to pembrolizumab after surgery reduced the risk of recurrence or death by 42% in high-risk melanoma. Investigators presented the results at the ESMO Congress 2026. The 42% figure is a relative risk reduction, and the full peer-reviewed data are still needed to judge the absolute benefit.

What happened

INTerpath-001 enrolled 1,137 patients whose melanoma had been surgically removed but who were at very high risk of relapse (stage IIB to IV). None had received prior cancer drug treatment. The trial was international and ran at 157 sites. Patients received either intismeran plus pembrolizumab or pembrolizumab alone.

The headline result for recurrence or death was a hazard ratio (HR) of 0.58 (95% CI 0.45–0.75; p<0.001), which corresponds to the 42% reduction. Among patients who remained recurrence-free beyond six months from the start of treatment, the HR was 0.42, a 58% reduction compared with pembrolizumab alone.

On safety, the investigators reported that the vaccine did not increase pembrolizumab's side effects. The vaccine itself caused transient, low-grade effects in some patients: injection-site pain, headache and chills.

The product is also called intismeran autogene, V940 or mRNA-4157. It is being developed jointly by MSD (Merck & Co) and Moderna. Professor Georgina Long, the global principal investigator, presented the data.

Why it matters

Surgery cures many patients with melanoma, but some with deeper primaries or nodal involvement relapse. Adjuvant anti-PD-1 therapy is already used to lower that risk. INTerpath-001 asks whether a personalized layer on top of checkpoint blockade can do better than checkpoint blockade alone.

The vaccine works differently from a preventive vaccine. A traditional vaccine prevents disease in healthy people. A therapeutic vaccine is given after diagnosis to train the immune system against an existing cancer, here against microscopic residual disease after resection.

According to the investigators, a tumor sample is sequenced to read its neoantigen "fingerprint." An mRNA vaccine is then made so the patient's own cells display those targets to the immune system. Pembrolizumab, in their description, "releases the brakes" that the tumor places on T cells. The vaccine supplies the target and the drug removes the brake.

The investigators call this the first Phase III study to show that a treatment built from a patient's own tumor can reduce the risk of cancer recurrence or death. That is the sponsors' and investigators' framing, and it should be weighed against the limitations below.

What to know for the USMLE

• Neoantigens are novel peptides created by tumor-specific somatic mutations. Because they are absent from normal tissue, they are foreign to the immune system and not subject to central tolerance. Melanoma has a high mutational burden, largely from UV-induced DNA damage (pyrimidine dimers, typically C→T transitions), so it is a good model for neoantigen-directed therapy.
• mRNA vaccine pathway: mRNA is translated in the host cell cytosol. The protein is degraded by the proteasome, and peptides are transported into the ER by TAP and loaded onto MHC class I. CD8+ cytotoxic T cells recognize the peptide–MHC I complex. Dendritic cells can also cross-present antigen to prime T cells, with CD4+ help.
• PD-1/PD-L1 axis: PD-1 is an inhibitory receptor on activated T cells. Tumor cells express PD-L1, and binding delivers an "off" signal. Pembrolizumab is a humanized IgG4 monoclonal antibody against PD-1 that blocks this interaction. Nivolumab is also anti-PD-1. Ipilimumab targets CTLA-4.
• Immune-related adverse events of checkpoint inhibitors are classic exam material: colitis, pneumonitis, hepatitis, dermatitis, and endocrinopathies such as thyroiditis, hypophysitis and adrenal insufficiency. The source reports that the vaccine did not increase pembrolizumab's side effects. Do not assume the immune-related adverse event profile disappears with checkpoint inhibitors.
• Melanoma basics: it arises from melanocytes (neural crest origin) and is stained by S-100, HMB-45 and Melan-A. The key prognostic factor is Breslow thickness (depth in mm), not horizontal diameter. Sentinel lymph node biopsy is used for staging. BRAF V600E is a common driver mutation with targeted therapy options.
• Adjuvant vs neoadjuvant: adjuvant therapy is given after surgery to eliminate micrometastatic disease. In this trial, "high risk" covered deeper invasion, spread to nearby tissue or lymph nodes, or distant metastases that had been resected.
• Hazard ratio interpretation: HR 0.58 means a 42% lower instantaneous risk of the event over time compared with control. A 95% CI that excludes 1.0 (0.45–0.75) indicates statistical significance. A relative risk reduction is not an absolute risk reduction, and Step questions often test this distinction.
• Study design vocabulary: a Phase III trial is a large, randomized comparison against standard care. Here the comparator arm was pembrolizumab alone, an active control rather than placebo alone.

Limitations

• Source type. The information comes from a news report based on an institutional presentation of conference results. It includes investigator quotes and enthusiastic language ("landmark," "foundational shift"). Judge the data, not the adjectives.
• Relative, not absolute. The 42% is a relative reduction. The source material does not give absolute recurrence rates, event counts or follow-up duration, so the real-world size of the benefit cannot be estimated here.
• Overall survival. The reported outcome is recurrence or death. The source does not report overall survival data, so whether the benefit translates into longer survival is not established by this material.
• The six-month analysis. The HR of 0.42 applies only to patients who remained recurrence-free beyond six months. Analyses restricted to a post-baseline group can be harder to interpret than the primary comparison. The primary result is the HR of 0.58.
• Safety detail. The source describes treatment as generally well tolerated with transient low-grade side effects. Full adverse-event rates, severity grading and discontinuation data should be checked in the full publication.
• Investigational status. Intismeran is not an approved therapy according to the source, which calls it investigational. Its commercial developers are co-sponsors, which is common in industry trials but worth noting.
• Population. Patients were stage IIB–IV and treatment-naive with resected disease. The results do not apply directly to other stages or to unresected metastatic melanoma.

FAQ

What is intismeran?

Intismeran (also called intismeran autogene, V940 or mRNA-4157) is an investigational, individualized mRNA-based neoantigen therapy. It is made from sequencing a patient's tumor and is used together with pembrolizumab. It is being developed by MSD and Moderna.

Is a therapeutic cancer vaccine the same as a preventive vaccine?

No. A preventive vaccine, such as one against HPV or hepatitis B, is given to healthy people to prevent infection. A therapeutic vaccine is given after a cancer diagnosis, here after surgery, to help the immune system find and kill remaining tumor cells.

Does a 42% risk reduction mean 42% of patients are cured?

No. A hazard ratio of 0.58 describes a relative reduction in the risk of recurrence or death over time compared with pembrolizumab alone. It does not mean 42% of patients avoid relapse. Absolute differences need the full publication.

Key takeaways

• In the Phase III INTerpath-001 trial (1,137 patients with resected stage IIB–IV melanoma), adding intismeran to pembrolizumab reduced the risk of recurrence or death by 42% (HR 0.58; 95% CI 0.45–0.75) versus pembrolizumab alone.
• For the USMLE, connect the pieces: tumor neoantigens, mRNA translation, MHC I presentation to CD8+ T cells, and PD-1 blockade by pembrolizumab. Also remember the difference between relative and absolute risk.
• The data come from a conference presentation covered by a news report. Absolute numbers, overall survival and full safety details await the full publication, and intismeran remains investigational.